Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Non-Current Liabilities: 2016-2024

Historic Other Non-Current Liabilities for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $3.8 million.

  • Tg Therapeutics' Other Non-Current Liabilities fell 36.22% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 36.22%. This contributed to the annual value of $3.8 million for FY2024, which is 961.62% up from last year.
  • Latest data reveals that Tg Therapeutics reported Other Non-Current Liabilities of $3.8 million as of FY2024, which was up 961.62% from $357,000 recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Other Non-Current Liabilities ranged from a high of $3.8 million in FY2024 and a low of $243,000 during FY2022.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $357,000 (2023), whereas its average is $1.5 million.
  • Per our database at Business Quant, Tg Therapeutics' Other Non-Current Liabilities plummeted by 61.62% in 2021 and then skyrocketed by 961.62% in 2024.
  • Yearly analysis of 5 years shows Tg Therapeutics' Other Non-Current Liabilities stood at $938,000 in 2020, then slumped by 61.62% to $360,000 in 2021, then tumbled by 32.50% to $243,000 in 2022, then skyrocketed by 46.91% to $357,000 in 2023, then soared by 961.62% to $3.8 million in 2024.